Comparison of 11C-4DST and 18F-FDG PET/CT imaging for advanced renal cell carcinoma: preliminary study

[1]  S. Berlangieri,et al.  In vivo imaging of cellular proliferation in renal cell carcinoma using 18F-fluorothymidine PET , 2014, Asia Oceania journal of nuclear medicine & biology.

[2]  Johannes A Langendijk,et al.  PET Imaging of Tumor Hypoxia Using 18F-Fluoroazomycin Arabinoside in Stage III–IV Non–Small Cell Lung Cancer Patients , 2013, The Journal of Nuclear Medicine.

[3]  D. Appelbaum,et al.  FDG-PET as a predictive biomarker for therapy with everolimus in metastatic renal cell cancer , 2013, Cancer medicine.

[4]  K. Ishiwata,et al.  The potential of proliferation imaging by 4'-[Methyl-11C] Thiothymidine (4DST) PET/CT for nodal staging of non-small-cell lung cancer , 2013 .

[5]  U. Tateishi,et al.  Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course , 2012, BMC Cancer.

[6]  K. Ishiwata,et al.  4′-[Methyl-11C]-Thiothymidine PET/CT for Proliferation Imaging in Non–Small Cell Lung Cancer , 2012, The Journal of Nuclear Medicine.

[7]  P. Sutphin,et al.  Targeting GLUT1 and the Warburg Effect in Renal Cell Carcinoma by Chemical Synthetic Lethality , 2011, Science Translational Medicine.

[8]  K. Ishii,et al.  Whole-Body Distribution and Brain Tumor Imaging with 11C-4DST: A Pilot Study , 2011, The Journal of Nuclear Medicine.

[9]  C. Kolbitsch,et al.  PTEN, pAKT, and pmTOR Expression and Subcellular Distribution in Primary Renal Cell Carcinomas and Their Metastases , 2011, Cancer investigation.

[10]  T. Powles,et al.  Sequential FDG-PET/CT as a Biomarker of Response to Sunitinib in Metastatic Clear Cell Renal Cancer , 2011, Clinical Cancer Research.

[11]  U. Tateishi,et al.  Impact of maximum Standardized Uptake Value (SUVmax) evaluated by 18-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG-PET/CT) on survival for patients with advanced renal cell carcinoma: a preliminary report , 2010, BMC Cancer.

[12]  D. Sabatini,et al.  mTOR: from growth signal integration to cancer, diabetes and ageing , 2010, Nature Reviews Molecular Cell Biology.

[13]  U. Tateishi,et al.  Evaluation of Response to Multikinase Inhibitor in Metastatic Renal Cell Carcinoma by FDG PET/Contrast-Enhanced CT , 2010, Clinical Nuclear Medicine.

[14]  M. Boijsen,et al.  Evaluation of sorafenib treatment in metastatic renal cell carcinoma with 2-fluoro-2-deoxyglucose positron emission tomography and computed tomography , 2009, Nuclear medicine communications.

[15]  Jong Wook Park,et al.  Significance of 18F‐fluorodeoxyglucose positron‐emission tomography/computed tomography for the postoperative surveillance of advanced renal cell carcinoma , 2009, BJU international.

[16]  N. Denko,et al.  Hypoxia, HIF1 and glucose metabolism in the solid tumour , 2008, Nature Reviews Cancer.

[17]  R. Motzer,et al.  Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial , 2008, The Lancet.

[18]  F. Waldman,et al.  Improved Identification of von Hippel-Lindau Gene Alterations in Clear Cell Renal Tumors , 2008, Clinical Cancer Research.

[19]  B. Delahunt,et al.  Outcome prediction for renal cell carcinoma: evaluation of prognostic factors for tumours divided according to histological subtype , 2007, Pathology.

[20]  J. Cheville,et al.  Ki‐67 and coagulative tumor necrosis are independent predictors of poor outcome for patients with clear cell renal cell carcinoma and not surrogates for each other , 2007, Cancer.

[21]  David B Seligson,et al.  Prognostic relevance of the mTOR pathway in renal cell carcinoma , 2007, Cancer.

[22]  David McDermott,et al.  Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. , 2007, The New England journal of medicine.

[23]  James Brugarolas,et al.  Renal-cell carcinoma--molecular pathways and therapies. , 2007, The New England journal of medicine.

[24]  Jun Toyohara,et al.  Evaluation of 4'-[methyl-14C]thiothymidine for in vivo DNA synthesis imaging. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[25]  G. Semenza,et al.  HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. , 2006, Cell metabolism.

[26]  C. Thompson,et al.  Akt-dependent transformation: there is more to growth than just surviving , 2005, Oncogene.

[27]  W. Kaelin.  The Von Hippel-Lindau Tumor Suppressor Gene and Kidney Cancer , 2004, Clinical Cancer Research.

[28]  S. Horvath,et al.  Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma. , 2004, The Journal of urology.

[29]  A. Alavi,et al.  Akt Stimulates Aerobic Glycolysis in Cancer Cells , 2004, Cancer Research.

[30]  H. Sasser,et al.  Clinical use of fluorodeoxyglucose F 18 positron emission tomography for detection of renal cell carcinoma. , 2004, The Journal of urology.

[31]  T. Olencki,et al.  F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  Richard D Klausner,et al.  The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. , 2002, Cancer cell.

[33]  H. Kirchner,et al.  Prognostic significance of Ki-67 immunostaining in nonmetastatic renal cell carcinoma. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  S. Fuhrman,et al.  Prognostic significance of morphologic parameters in renal cell carcinoma , 1982, The American journal of surgical pathology.

[35]  R. Wahl,et al.  Fluorodeoxyglucose Positron Emission Tomography Correlates With Akt Pathway Activity but Is Not Predictive of Clinical Outcome During mTOR Inhibitor Therapy , 2009 .

[36]  Kazutoshi Suzuki,et al.  Feasibility studies of 4'-[methyl-(11)C]thiothymidine as a tumor proliferation imaging agent in mice. , 2008, Nuclear medicine and biology.

[37]  E. Henske,et al.  Activation of the mTOR signaling pathway in renal clear cell carcinoma. , 2007, The Journal of urology.